Foundayo, Saxenda, Wegovy, Zepbound are approved for weight management, in adults with obesity, or with overweight and a weight-related condition. Mounjaro, Ozempic, Rybelsus and Ozempic tablets, Trulicity, Victoza are approved for type 2 diabetes and related uses. All need a prescription, and a prescriber decides.
Word for word from each manufacturer's FDA label on DailyMed, read every day. Newest revision here: Aug 28, 2026.
Sections 1 and 4 of each label
What each brand is approved for, and who should not take it
Foundayo
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Who should not take Foundayo
A personal or family history of MTC or in patients with MEN 2
Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists
as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Who should not take Mounjaro
A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Who should not take Ozempic
A personal or family history of MTC or in patients with MEN 2
A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Who should not take Rybelsus and Ozempic tablets
A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets
SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
Adults with overweight in the presence of at least one weight-related comorbid condition.
Who should not take Saxenda
Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in SAXENDA. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with SAXENDA
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Who should not take Trulicity
Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY
as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus,
to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
Who should not take Victoza
personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
serious hypersensitivity reaction to liraglutide or to any of the excipients in VICTOZA. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with VICTOZA
WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition.
for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.
WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:
to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.
Who should not take Wegovy
a personal or family history of MTC or in patients with MEN 2
a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY
ZEPBOUND is indicated in combination with a reduced-calorie diet and increased physical activity:
to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Who should not take Zepbound
A personal or family history of MTC or in patients with MEN 2
Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide
The labels say “obesity” or “overweight” rather than a number. By the CDC's categories, overweight is a BMI of 25 to under 30 and obesity is 30 or higher. Pivotal trials set their own entry rules: SURMOUNT-1 enrolled a BMI of 30 or more, or 27 or more with a condition such as high blood pressure, high cholesterol, sleep apnea or heart disease. Insurers and prescribers may apply their own rules.
Questions
Who qualifies: common questions
Which GLP-1s are approved for weight loss?
Foundayo, Saxenda, Wegovy, Zepbound. Each is approved for adults with obesity, or with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. Each label's own wording is on this page.
Which GLP-1s are approved only for type 2 diabetes, not weight loss?
Mounjaro, Ozempic, Rybelsus and Ozempic tablets, Trulicity, Victoza are approved for type 2 diabetes and related uses listed in each label, not for weight loss itself. A prescriber can decide to use a medicine outside its label, and insurers usually cover only labeled uses.
Is a GLP-1 approved for PCOS?
No. None of the current FDA labels here lists polycystic ovary syndrome as an approved use. A prescriber can decide to use a medicine outside its label, and insurers usually cover only labeled uses.
Is a GLP-1 approved for type 1 diabetes?
No. None of the current FDA labels here lists type 1 diabetes as an approved use. A prescriber can decide to use a medicine outside its label, and insurers usually cover only labeled uses.
Is a GLP-1 approved for sleep apnea?
Zepbound lists it among the uses in the FDA label. Each label's wording is on this page.
Is a GLP-1 approved for fatty liver disease?
Wegovy lists it among the uses in the FDA label. Each label's wording is on this page.
Is a GLP-1 approved for heart disease?
Mounjaro, Ozempic, Rybelsus and Ozempic tablets, Trulicity, Victoza, Wegovy list it among the uses in the FDA label. Each label's wording is on this page.
What BMI do you need for a GLP-1?
The labels state "obesity" or "overweight" with a weight-related condition rather than a number. By the CDC's definition, overweight is a BMI of 25 to under 30 and obesity is 30 or higher. Pivotal trials such as SURMOUNT-1 enrolled a BMI of 30 or more, or 27 or more with a condition such as high blood pressure, high cholesterol, sleep apnea or heart disease. A prescriber or insurer may apply their own rules.
Can you get a GLP-1 without diabetes?
Yes. Foundayo, Saxenda, Wegovy, Zepbound are approved for weight management in people without diabetes, under the conditions each label states.
Who qualifies for Foundayo?
Its FDA label says: FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Who qualifies for Mounjaro?
Its FDA label says: MOUNJARO is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Who qualifies for Ozempic?
Its FDA label says: OZEMPIC is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Who qualifies for Rybelsus and Ozempic tablets?
Its FDA label says: RYBELSUS and OZEMPIC tablets are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Who qualifies for Saxenda?
Its FDA label says: SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition.
Who qualifies for Trulicity?
Its FDA label says: TRULICITY is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Who qualifies for Victoza?
Its FDA label says: VICTOZA is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
Who qualifies for Wegovy?
Its FDA label says: WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition. for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH
Who qualifies for Zepbound?
Its FDA label says: ZEPBOUND is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Whether a medicine is right for you is a decision for you and a licensed prescriber.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.